2 transcripts
ABT
Earnings call transcript
NYSE
2024 Q2
18 Jul 24
for both chronic and temporary conditions.
In Neuromodulation, growth of 8% was driven by strong demand in international markets for our Eterna rechargeable
ABT
Earnings call transcript
NYSE
2023 Q2
20 Jul 23
diabetic neuropathy and chronic back pain for those who have not had or are not eligible for back surgery.
So in summary, we exceeded expectations on both
- Prev
- 1
- Next